InvestorsHub Logo
Followers 130
Posts 14996
Boards Moderated 1
Alias Born 06/04/2018

Re: None

Wednesday, 04/03/2019 3:11:01 PM

Wednesday, April 03, 2019 3:11:01 PM

Post# of 810
News: $ACHN Achillion Announces Enrollment Milestone in Phase 2 Trials for C3 Glomerulopathy

- Enrolled 23 patients in ACH-4471 Phase 2 C3G six and 12-month clinical trials - - Targeting end-of-Phase 2 meeting with FDA in fourth quarter of 2019 - BLUE BELL, Pa., April 03, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutic...

In case you are interested https://marketwirenews.com/news-releases/achillion-announces-enrollment-milestone-in-phase-2-trials-for-c3-glomerulopathy-7938338.html